Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00614679 · ClinicalTrials.gov registry record · Phase 1
A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia
A Phase 1 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00614679 is a Phase 1 study that has completed, run by University of California, San Diego. The registered enrollment target is 18 participants.
The verdict
NCT00614679, a Phase 1 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The primary objective is to investigate the ability of systemic intravenous antibiotic plus antibiotic/anti-biofilm (i.e. N-acetylcysteine) lock catheter technique in eradicating uncomplicated catheter associated bacteremia and salvaging the infected vascular catheter. Secondary objectives include duration to clearance of bacteremia, future recurrence of bacteremia, need for catheter removal and death.
Interventions
- DRUG catheter lock solution consisting of N-acetylcystein, tigecycline and heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00614679
The ClinicalTrials.gov registry entry for NCT00614679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which catheter lock solution consisting of N-acetylcystein, tigecycline and heparin is the first listed.
NCT00614679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00614679 about?
NCT00614679 is a clinical study titled "A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia". The primary objective is to investigate the ability of systemic intravenous antibiotic plus antibiotic/anti-biofilm (i.e. N-acetylcysteine) lock catheter technique in eradicating uncomplicated catheter associated bacteremia and salvaging the infected vascular catheter. Secondary objectives include d...
What is the current status of trial NCT00614679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2006-10. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00614679?
The interventions under investigation include: catheter lock solution consisting of N-acetylcystein, tigecycline and heparin (DRUG).
Who is sponsoring clinical trial NCT00614679?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.